CIN No.: L24230TG1995PLC020093



CONCORD DRUGS LIMITED

Regd. Office & Factory: Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office: 3-11-451, L B Nagar, Hyderabad - 500074

E-mail: concorddrugsltd@gmail.com

Ph.No: +91 9052779505

Website: www.concorddrugs.in

Date: 09.08.2024

To,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal St, Fort, Mumbai,
Maharashtra 400001

Scrip Code: 538965

Dear Sir/Madam,

Sub: Discrepancies in Financial Results Email dated 07.08.2024 received from BSE Limited.

The Queries raised by BSE Limited and our clarifications are as follows:

Query: Standalone Results- Cash Flow Statement for Standalone Results not Received in Pdf for Year Ended – March 2024.

Reply: We hereby enclosing Cash Flow Statement for Standalone Results in PDF format. (Due to a scan error, we erroneously unable to upload the missing document; however, the accurate figures have already been uploaded in XBRL format on the actual date as complied)

This is for the information and records of the Exchange, please.

Thanking you

Yours Sincerely,

For Concord Drugs Limited

SEELAM Digitally signed by SEELAM NAGI REDDY Date: 2024.08.09
18:28:24 + 45*30*

NAGI REDDY SEELAM

Chairman & Managing Director

(DIN: 01764665)



Concord Drugs Limited Survey No 249, Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana Statement of assets and Liabilities audited (standalone and Consolidated) as on 31st March 2024 Rs In lakhs

		Sta	ndalone	Consolidated		
Particulars	Note	As on 31st March, 2024	As At March 31, 2023	As on 31st March , 2024	As At March 31, 2023	
ASSETS					-	
Non-current assets						
(a) Property, plant and equipment	3	1,098.64	1,221.64	1,103.62	1,228.33	
(b) Capital Work-in Progress	3	163.05	92.09	163.05	92.09	
(b) Investment property	3	63.95	63.95	63.95	63.95	
(e) Goodwill	4	-			-	
Financial assets		-				
(a) Investments	4	161.50	141.50	84.06	89.36	
(b) Loans & Advances	4	4.46	3.73	4.46	3.73	
Other Non current assets	5	-				
Total Non - Current Assets		1,491.61	1,522.90	1,419.14	1,477.45	
Current Assets						
Inventories	7	1,849.93	1,750.40	2,292.31	2,006.47	
Financial assets		-		,	2,000.47	
(a) Investments		-				
(b) Trade receivables	6	2,106.95	1,635.42	1,982.67	1,581.01	
(c) Cash and cash equivalents	8	13.71	7.52	14.54	7.84	
(d) Bank balances other than (c) above	8	3.10	2.10	3.10	2.10	
(e) Other Current Financial Assets	9	4.69	14.04	4.69	14.04	
Other current assets	10	159.84	730.98	164.20	734.20	
Total Current assets		4,138.21	4,140.46	4,461.50	4,345.64	
Total Assets		5,629.82	5,663.37	5,880.64	5,823.10	
EQUITY AND LIABILITIES					3,020,12	
Equity						
Equity share capital						
Other equity	11 12	1,000.00	931.55	1,000.00	931.55	
other equity	12	2,381.78	2,238.88	2,381.78	2,238.88	
Total Equity		3,381.78	3,170.42	3,381.78	3,170.42	
Non-current liabilities						
Financial Liabilities						
(a) Borrowings	13	2.67	101.71	64.54	101.12	
(b) Trade payables		-	101.71	04.54	191.13	
Deferred tax liabilities, net	14	48.15	54.48	47.33	53.68	
Provisions	15	252.88	246.38	252.88	246.38	
Government Grants	13	-	-	232.00	240.38	
Total Non-current liabilities		303.70	402.57	364.76	491.20	
Current liabilities						
Financial liabilities						
(a) Borrowings	16	1,398.13	1,378.47	1 504 97	4 400 50	
(b) Trade payables	17	354.67	514.52	1,594.87	1,422.60	
(c) Other Current financial liabilities	18	92.46	82.74	343.75	527.22	
Current tax liabilities, net	15	20.24	34.77	92.46	82.74	
Other current liabilities	19	78.85	79.86	22.34	38.12	
Total Current liabilities		1,944.34	2,090.37	80.70 2,134.10	90.79 2,161.48	
Cotal liabilities					2,202.40	
Fotal liabilities		2,248.04	2,492.94	2,498.86	2,652.67	
Total Equity and liabilities		5,629.82	5,663.37	5,880.64	5,823.10	

By Order of the Board For Concord Drugs Limited

Managing Director DIN: 01764665

Place: Hyderabad Date: 30.05.2024



Concord Drugs Limited Survey No 249, Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana Statement of standalone assets and Liabilities (audited) as on 31st March 2024 Rs in Lakhs

Statement of standalone assets and	d) as on 31st March 2024	Rs in Lakhs		
Particulars	Note	As on 31st March 2024	As on March 31, 2023	
ASSETS				
Non-current assets				
(a) Property, plant and equipment	3	1,098.64	4 224 64	
(b) Capital Work-in Progress	3	163.05	1,221.64	
(b) Investment property	3	63.95	92.09 63.95	
Financial assets				
(a) Investments	4	161.50	141.50	
(b) Loans & Advances	4	4.46	141.50 3.73	
Other Non current assets	5	4.40	3./3	
Total Non - Current Assets		1,491.61	1,522.90	
Current Assets				
Inventories	7	1,849.93	1,750.40	
Financial assets		2,015.55	1,750.40	
(a) Investments				
(b) Trade receivables	6	2,106.95	1 635 43	
(c) Cash and cash equivalents	8	13.71	1,635.42	
(d) Bank balances other than (c) above	8	3.10	7.52 2.10	
(e) Other Current Financial Assets	9	4.69	14.04	
Other current assets	10	159.84	730.98	
Total Current assets		4,138.21	4,140.46	
Total Assets		5 620 82		
		5,629.82	5,663.37	
EQUITY AND LIABILITIES Equity				
Equity share capital	11	1,000.00	931.55	
Other equity	12	2,381.78	2,238.88	
Total Equity		3,381.78	3,170.42	
Non-current liabilities				
Financial Liabilities				
(a) Borrowings	13	2.67	101.71	
(b) Trade payables			101.71	
Deferred tax liabilities, net	14	48.15	54.48	
Provisions	15	252.88	246.38	
Government Grants Fotal Non-current liabilities	13	303.70	-	
		303.70	402.57	
Current liabilities				
inancial liabilities				
(a) Borrowings	16	1,398.13	1,378.47	
(b) Trade payables	17	354.67	514.52	
(c) Other Current financial liabilities	18	92.46	82.74	
Current tax liabilities, net	15	20.24	34.77	
Other current liabilities	19	78.85	79.86	
otal Current liabilities		1,944.34	2,090.37	
otal liabilities		2,248.04	2,492.94	
otal Equity and liabilities		5,629.82	5,663.37	
		Drugs		

Place: Hyderabad Date: 30.05.2024 Order of the Board Concord Drugs Limited

Managing Director

Concord Drugs Limited Survey No 249, Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

Audited Statement Of Consolidated Profit and Loss for the Period ended 31st March '24 Amount in Lakhs Standalone Consolidated As on 31st As at March 31. As on 31st March **Particulars** As at March 31, Note March 2024 2023 ,2024 2023 Revenue from Operations a. Net sales from Operations 20 4,326.07 5.131.43 4,492,45 5,208.06 II Other Income 21 0.93 0.89 0.93 0.89 III Total Revenue (I+II) 4,327.00 5,132.31 4,493.38 5,208.94 Expenses a.Cost of Material Consumed 22 3,370.81 4.035.53 3,365.90 4,116.16 b. Changes in Inventories of finished goods, work-in-progress 23 -40.49 51.56 -40.49 and stock-in-trade -15.67 c. Employees Benefit Expenses 24 495.04 463.42 607.63 491.90 d. Finance Costs 25 158.98 162.45 186.76 170.62 e. Depreciation and Amortisation expense 3 153.82 160.25 155.54 162.56 f. Other expenses 26 132.99 146.56 155.15 158.49 **Total Expenses** 4,271.16 5,019.76 4,430.48 5,084.05 Profit/ (Loss) before Exceptional item and tax (III-IV) 55.84 112.56 62.90 124.89 V **Exceptional Items** VI Profit/ (Loss) before tax (V+VI) 55.84 112.56 62.90 124.89 VII Tax Expense: 13.90 23.34 15.66 26.34 VIII a. Current tax 20.24 34.77 22.01 37.87 b. Deferred tax charge/credit -6.34-11.43 -6.36 -11.53 IX Profit/ (Loss) for the period (VII-VIII) 41.94 89.22 47.24 98.55 X Other Comprehensive Income Items that will not be reclassified to profit or loss Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) 41.94 89.22 47.24 98.55 (IX+X) XI Paid-up equity share capital 1,000.00 931.55 1,000.00 931.55 (Face value of the share- Rs. 10 each) XII Earnings per share (of Rs. 10 each) XIII a. Basic (in Rs) 0.42 0.96 0.47 1.06 b. Diluted (in Rs) 0.42 0.96 0.47 1.06

Place: Hyderabad Date: 30.05.2024 By Order of the Board
For Concord Drugs Limited

Concord Drugs Limited Survey No 249, Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana

	Particulars	Note	As on 31St March' 2024	As at March 31, 2023
1	Revenue from Operations			73 de 14 de 17 de 17 2025
	a. Net sales from Operations	20	4,326.07	5,131.43
11	Other Income	21	0.93	0.89
Ш	Total Revenue (I+II)		4,327.00	5,132.31
IV	Expenses			
	a.Cost of Material Consumed	22	3,370.81	4,035.53
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	23	-40.49	51.56
	c. Employees Benefit Expenses			51.50
	d. Finance Costs	24	495.04	463.42
	e. Depreciation and Amortisation expense	25	158.98	162.45
	f. Other expenses	3	153.82	160.25
	Total Expenses	26	132.99	146.56
			4,271.16	5,019.76
v	Profit/ (Loss) before Exceptional item and tax (III-IV)		55.84	112.56
VI	Exceptional Items		•	
VII	Profit/ (Loss) before tax (V+VI)		55.84	112.56
VIII	Tax Expense: a. Current tax		13.90	23.34
VIII			20.24	34.77
IX	b. Deferred tax charge/credit		-6.34	-11.43
X	Profit/ (Loss) for the period (VII-VIII)		41.94	89.22
^	Other Comprehensive Income		-	-
	Items that will not be reclassified to profit or loss			500 - F
	Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)		41.94	89.22
ΧI	Paid-up equity share capital	-	1,000.00	931.55
	(Face value of the share- Rs. 10 each)		1,000.00	931.55
XII	Earnings per share (of Rs. 10 each)			
XIII	a. Basic (in Rs)		0.42	0.00
	b. Diluted (in Rs)		0.42	0.96
			O.42	0.96

Place: Hyderabad Date: 30.05.2024 By Order of the Board For Concord Drugs Limited

	STATEMENT OF AUDITED Consolidated FINANCIAL RESU	JLTS FOR THE QUAR	RTER ENDED 31st M	arch 2024		
						[Rs. in Lakh
			Quarterly ended		Year	Ended
Particu	lars	31-Mar-24	31-Dec-23	31-Mar-23	31-Mar-24	31-Mar-23
I	Revenue from Operations	(Audited)	(Un Audited)	(Audited)	(Audited)	(Audited)
	a. Net sales from Operations					
	b. Other Operating Income	1,564.24	1,278.37	1,230.64	4,492.45	5,208.
II	Other Income	0.11	0.00	0.08	0.93	0.8
III	Total Revenue (I+II)	1,564.36	1,278.37	1 220 54		
IV	Expenses	1,504.50	1,2/0.3/	1,230.71	4,493.38	5,208.9
	a.Cost of Material Consumed	1,183.24	1,096.16	1 005 05	2244	
	b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	142.04	-84.06	1,025.05	3,365.90	4,116.1
	c. Employees Benefit Expenses	169.06	153.93	-59.97	-40.49	-15.6
	d. Finance Costs	50.38	49.67	130.04	607.63	491.9
	e. Depreciation and Amortisation expense	39.44	38.93	49.83	186.76	170.6
	f. Other expenses	34.93	49.43	33.03	155.54	162.5
	Total Expenses	1,619.09	1,304.06	38.67	155.15	158.4
	Profit/ (Loss) before Exceptional item and tax (III-IV)	-54.73	-25.69	1,216.64 14.07	4,430.48	5,084.0
V	Exceptional Items		-23.09	14.07	62.90	124.8
VI	Profit/ (Loss) before tax (V-VI)	-54.73	-25.69	14.07	62.90	124.8
VII	Tax Expense:	-20.85	-1.57	-2.20	15.66	26.3
	a. Current tax	-19.93	-0.43	5.49	22.01	37.8
0	b. Deferred tax charge/credit	-0.92	-1.14	-7.69	-6.36	-11.5
IX	Profit/ (Loss) for the period (VII-VIII)	-33.88	-24.12	16.27	47.24	98.5
X	Other Comprehensive Income			10.27	47.24	90.3
	Items that will not be reclassified to profit or loss				- 1	
	Total Comprehensive Income for the period (comprising profit and other				1	-
	comprehensive income for the period) (IX+X)	-33.88	-24.12	16.27	47.24	98.5
XI	Paid up Capital	1,000.00	1,000.00	931.55	1,000.00	931.5
	(Face value of the share- Rs. 10 each)		2,000.00	751.55	1,000.00	931.5
	Other Equity	2,381.78	2,417.05	2,238.88	2,381.78	2,238.8
XII	Earnings per share (of Rs. 10 each)			2,250.00	2,501.76	2,230.0
XIII	a. Basic (in Rs)	-0.34	-0.24	0.17	0.47	
	b. Diluted (in Rs)	-0.34	-0.24	0.17	0.47	1.0
		-0.54	-0.24	0.17	0.47	1.0
Votes:						
1	The finnacial results of the company hav been prepared in accordance with the Indian Accread with the relevant rules issued there under.	counting Standards	(Ind AS) prescribed	under section 133	of the Companie	es Act, 2013,
2	The above Consolidated financial results as reviwed by the audit committee have been a	pproved by Board o	of Directors at its me	eting held on 30th	May,2024	-
3	Figures of the corresponding previous periods are regrouped and reclassified wherever co					22.7.1
4	During the year The company has Acquired anothe 2,00,000 equity Shares of Proton Rem for a total consideration of 20,00,000 (2,00,000 equity shares of Rs.10 each).	edies Private limite	ed(100% subsidary) l	by increasing the	authorised capita	l of subsidairy
5	The results are also available on the webiste of the Company www.concorddrugs.in					
			11.0		y Order of the B	
			n n n n	JEN S	or Concord Drug	gs Limited
ace. H	yderabad		1191	15.11	5. Nota	-

Date: 30.05.2024



Particulars Revenue from O a. Net sales from b. Other Operatin II Other income III Total Revenue () IV Expenses a.cost of Material b. Changes in Invo c. Employees Ben d. Finance Costs c. Deprectation ar f. Other expenses Total Expenses Profit/ (Loss) be V Exceptional Item VI Tax France.	Revenue from Operations a. Net sales from Operations b. Other Operating Income Other Income Total Revenue (1+11) Expenses a.Cost of Material Consumed b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	24 Mar. 24	S. Contraction of the second			
I Reven a. Net s b. Other I III Total R IV Expens c. Emplo d. Finar e. Depri f. Other f. Other Total E Profit V VI Profit V VI Tay Fy	le from Operations ales from Operations Operating Income ncome evenue (I+II) es f Material Consumed ges in Inventories of finished goods, work-in-progress and stock-in-trade	DA Man 24	Quarterly ended		Year E	Year Ended
	les from Operations les from Operations Operating Income ncome Name [1-11] For Material Consumed I Material Consumed Ses in Inventories of finished goods, work-in-progress and stock-in-trade	31-Mar-24 (Audited)	31-Dec-23	31-Mar-23	31-Mar-24	31-Mar-23
	ules from Operations Operating Income ncome evenue (I+II) es f Material Consumed f Material Gonsumed ges in Inventories of finished goods, work-in-progress and stock-in-trade			(2000)	(manner)	(named)
	represents income evenue (I+II) es f Material Consumed ges in Inventories of finished goods, work-in-progress and stock-in-trade	1,446.56	1,262.44	1,154.01	4,326.07	5,131.43
	es evenue (I+II) es f Material Consumed ges in Inventories of finished goods, work-in-progress and stock-in-trade yees Benefit Expenses	0.11	0.01	80.0	0.93	0.89
	es f Material Consumed ges in Inventories of finished goods, work-in-progress and stock-in-trade yyees Benefit Expenses	1.446.68	1.262.44	1.154.09	4 327 00	E 122 21
	f Material Consumed sees for finished goods, work-in-progress and stock-in-trade yyees Benefit Expenses			in the second	00:1754	10.761,6
	jes in Inventories of finished goods, work-in-progress and stock-in-trade yees Benefit Expenses	1,279.31	1,043.65	944.42	3,370.81	4.035.53
	yees Benefit Expenses	-8.96	1.21	7.26	-40.49	51.56
		125.39	120.33	101.56	495.04	463.42
		37.74	43.18	41.66	158.98	162.45
	e. Depreciation and Amortisation expense	39.01	38.49	30.72	153.82	160.25
	expenses	32.07	41.11	26.74	132.99	146.56
	penses	1,504.56	1,287.95	1,152.36	4,271.16	5,019.76
	Front, (Loss) before Exceptional item and tax (III-IV) Exceptional frams	-57.88	-25.51	1.73	55.84	112.56
	Profit (Loss) before tax (V-VI)	.57 88	25 51			
	Tax Expense:	00.75	16.63-	1.73	55.84	117.56
	L tax	21.50	1.57	-5.20	13.90	23.34
	b. Deferred tax charge/credit	000	-0.43	2.39	20.24	34.77
	Profit (Loss) for the period (VII-VIII)	-35 40	-1.14	607	-6.34	-11.43
	Other Comprehensive Income		66:67	0.93	4T.94	89.22
Items th	Items that will not be reclassified to profit or loss					
Total Co	Total Comprehensive Income for the period Comprising profit and other					,
	comprehensive income for the period) (IX+X)	-35.40	-23.95	6.93	41.94	89.22
XI Paid up	Paid up Capital	1,000.00	1.000.00	931 55	1 000 00	93155
(Face va	(Face value of the share- Rs. 10 each)				2000	00.107
	quity	2,381.78	2,417.18	2,238.88	2,381.78	2,238,88
	Earnings per share (of Rs. 10 each)					
XIII a. Basic (in Rs)	in Rs)	-0.35	-0.24	0.07	0.42	0.96
b. Diluted (in Rs)	I (in Rs)	-0.35	-0.24	0.07	0.42	0.96
Notoc						
read with	Ine findacial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.	Accounting Standard	s (Ind AS) prescribed	d under section 133	of the Companie	es Act, 2013,
The ahov						
2	e standarone initaridal results as reviwed by the audit committee have been approved by Board of Directors at its meeting held on 30.05.2024	proved by Board of D	irectors at its meeting	ng held on 30.05.20	124	
3 Figures of	figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current period's presentation.	onsidered necessary	to correspond with	current period's pr	resentation.	
	The results are also available on the webiste of the Company was concordering in					
4	The state of the s					
					By Order of the Board	oard
			010	in	For Concord Drugs Limited	s Limited
Place: Hyderabad			ou		Dire	1

4 Avderab

Statement Audited Consolidated Cash flow for the year ended 31	.03.2024			
Particulars	.03.2024 As or	Amount in Lakhs As at		
	31st March		March 31	
A. CASH FLOW FROM OPERATING ACTIVITIES			Widten 5.	, 2023
Profit Before Tax Adjustments for :		62.895		124.89
Profit on sale of ASSets				
Depreciation and amortisation expense				
Finance costs	155.539		162.558	
Interest income	186.757		163.712	
Provision for Gratutiy	-0.929		-0.603	
11013ion for diacuty			0.00	
Operating profit before working capital changes		341.367		325.667
Changes in working capital: (Refer Note 40)		404.263		450.557
Adjustments for (increase) / decrease in operating assets:				
Financial Assets				
Trade receivables				
Loans and Advances	-401.665		1,287.924	
Other Non Current assets	-0.733		-0.543	
Inventories				
Other Current assets	-285.835		-68.632	
Other bank balances	570.000		-593.689	
Other Current financial Assets	-1.000		-	
Other current infancial Assets	9.350		-3.960	
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables				
Borrowings	-183.473		-854.840	
Other current financial liabilities				
Other current liabilities	9.713		3.940	
Current tax liabilities, net	-10.091		-22.960	
Provisions	-15.786		-32.363	
Deferred tax on amalgamation	6.500		38.744	
Cash generated from operations				
Net income tax paid		101.241		204.178
Net cash flow from operating activities (A)		-22.013		-37.874
B. CASH FLOW FROM INVESTING ACTIVITIES		79.228		166.304
Capital expenditure on fixed assets, including capital advances				
(Refer Note (iii) below)	-101.79		-85.658	
Proceeds from maturiy of fixed deposits				
Investment				
- Subsidiaries				
- Others	0.000		-141.500	
Net cash (used in) / flow from investing activities (B)	0.929		0.603	
C. CASH FLOW FROM FINANCING ACTIVITIES		-100.864		-226.555
Proceeds from issue of equity shares	60 453		450.0	
Finance costs	68.453		188.668	
Repayment of Borrowings	-186.757		-163.712	
Repayment of short term Borrowings	-126.583		-3.456	
Govt Grants	172.261		-15.577	
Other equity Adjustment	100.000		-	
let cash flow (used in) financing activities (C)	100.968		56.475	
,		28.342		62.398
let (decrease) in Cash and cash equivalents (A+B+C)				
ash and cash equivalents at the beginning of the year		6.706		2.147
Effect of exchange differences on translation of foreign		7.836		5.689
currency Cash and cash equivalents				
ash and cash equivalents at the end of the year (Refer Note (i) below)				
Comprises:		14.54		7.836
alances with Banks				
Others		13.71		0.001
		0.83		7.836
		14.54		7.836
	DY		Order of the Bo	
	1/8	C TOTAL O	r Concord Drug	s Limited
	10/	1511	5. No no	4
lace: Hyderabad	Concord) Eil	anaging Directo N: 01764665	7

Vdera

As at March 31,2 A. CASH FLOW FROM OPERATING ACTIVITIES Profit Before Tax Addistantents for: Profit Before Tax Addistantents for: Profit and amonitisation expense Loss / [gini] on sale of PPE (net) Finance costs Expenses recognised in respect of equity-settled share-based payments Interest income Provision for Gratuty Operating profit before working capital changes Canages in working capital: (Refer Note 40) Adjustments for (Increase) / decrease in operating assets: Trade receivables Loans and Advances Other Kon Current assets Other Kon Current assets Other Current francial Assets Adjustments for increase / decrease) in operating liabilities: Trade receivables Loans and Advances Other Current francial liabilities Other current francial lia	Concord Drugs Limited Survey No 249, Brahmanapally Village Statement Audited Standalone Cash flow for the year ended 31st	March, 2024		Rs in L	akhs
A. CASH FLOW FROM OPERATING ACTIVITIES Profit Before Tax Adjustments for: Profit on sale of ASSets Depreciation and amortisation expense Loss / (gain) on sale of PPE (net) Finance costs Expenses recognised in respect of equity-settled share-based payments Interest income Provision for Gratuty Operating profit before working capital changes Provision for Gratuty Operating profit before working capital changes Provision for Gratuty Operating profit before working capital changes Provision for Gratuty Operating profit before working capital changes Provision for Gratuty Operating profit before working capital changes Provision for Gratuty Operating profit before working capital changes Provision for Gratuty Operating profit before working capital changes Provision for Gratuty Operating profit before working capital changes Provision for Gratuty Operating profit before working capital changes Provision for Gratuty Operating profit before working capital changes Provision for Gratuty Operating profit before working capital changes Operating profit before Operating profit before Operating p	Particulars				
Profit Refore Tax		31st March, 2024		March 3	1, 2023
### Additional Profile and Set of ASSets Depreciation and amortisation expense Loss / (gain) on sale of PPE (net) Finance costs Expenses recognised in respect of equity-settled share-based payments Interest income Provision for Gratuty Operating profit before working capital changes Changes in working capital changes Adjustments for (increase) / decrease in operating assets: Financel Assets Trade receivables Loans and Advances Other Non Current assets Under Non Current assets Other Non Current assets Other Non Current assets Other Current and Sets Other Current in Advances Other Current assets Other Current in Current assets Other Current assets Other Current in Curr	A. CASH FLOW FROM OPERATING ACTIVITIES				
Prof. to rasle of ASSets Depreciation and amortisation expense 153.823 160.25	Profit Before Tax		55.838		112.55
Depreciation and amortisation expense 153.823 160.25	Adjustments for:				111.55
158.982 155.54	Profit on sale of ASSets				
158.982 155.54	Depreciation and amortisation expense	153.823		160.25	
Expenses recognized in respect of equity-settled share-based payments Interest income Provision for Gratutiy 311.876 Operating profit before working capital changes 367.714 Changes in working capital: (Refer Note 4D) Adjustments for (increase) / decrease in operating assets: Financial Assets Trade receivables	Loss / (gain) on sale of PPE (net)				
Interest Income		158.982		155.54	
Provision for Gratutiy	Expenses recognised in respect of equity-settled share-based payments				
		-0.929		-0.60	
Operating profit before working capital changes	Provision for Gratutiy				
Changes in working capitals. (Refer Note 40) Adjustments for (increase) / decrease in operating assets: Financial Assets Trade receivables Loans and Advances Other Non Current assets Inventories Other Current assets Other Current assets Other Current financial Assets Other Current financial Assets Adjustments for increase / (decrease) in operating liabilities: Trade payables Borrowings Other current financial liabilities Other current financial liabilities Trade payables Other current financial liabilities Other current liabilities Ot			311.876		315.19
Adjustments for (Increase) / decrease in operating assets: Financial Assets Trade receivables Loans and Advances O-,54 Other Non Current assets Inventories Other Current financial Assets Other Current financial Assets Adjustments for increase / (decrease) in operating liabilities: Trade payables Borrowings Other current financial liabilities Other current liabilities Other current lia			367.714		427.74
Financial Assets Loans and Advances Other Non Current assets Inventories Other Current assets Other Current assets Other Current financial Assets Adjustments for increase / (decrease) in operating liabilities: Trade payables Other current financial liabilities Other current fina					
Trade receivables -471.528 650.43 1-0.54					
Cash Finds Cash Repeated from aperating activities (A) Cash Flow from activities (A) Cash Flow from activities (B) Cash Flow from activities (B) Cash Flow from activities (B) Cash Flow from investing activities (B) Cash and cash equivalents (A) Cash and cash equivalents (C) Cash and cash equivalents (Cheron process) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cash and cash equivalents at the end of the year (Refer Note (ii) below) Cas					
Other Non Current assets Inventories		-471.528		650.43	
Inventories		-0.733		-0.54	
Other Current assets Other bank balances Other Current financial Assets 1-0.00 Other Current financial Assets 1-0.00 Other Current financial Assets 1-0.00 Adjustments for increase / (decrease) in operating liabilities: Trade payables Borrowings Other current financial liabilities Other current financial liabilities Other current tax liabilities Other current tax liabilities Other current tax on amalgamation Cash generated from operations Net income tax paid Let cash flow from operating activities (A) In 195.986 CASH FLOW FROM INVESTING ACTIVITIES Capital expenditure on fixed assets, including capital advances (Refer Note (ii) below) Proceeds from maturiy of fixed deposits Investment - Subsidiaries - Others Obidiedn income received - Subsidiary - Others - dividend from mutual funds et cash (lused in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs Repayment of Borrowings Repayment of Borrowings Repayment of short term Borrowings Repayment					
Other bank balances Other Current financial Assets Other Current financial Assets Adjustments for increase / (decrease) in operating liabilities: Trade payables Borrowings Other current financial liabilities Other current financial liabilities Other current financial liabilities Other current liabilities, net -1.014 -25.86 Current tax non amalgamation Cash generated from operations Net income tax paid tect cash flow from operating activities (A) CASH FLOW FROM INVESTING ACTIVITIES Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below) Proceeds from maturiy of fixed deposits Investment -5. Universiment -5. Universiment -5. Universiment -5. Universiment -5. Universiment -6. Universiment -6. Universiment -7. Universime		-99.525		-1.41	
Other Current financial Assets Adjustments for increase / (decrease) in operating liabilities: Trade payables Borrowings Other current financial liabilities Other current sinabilities Other current financial liabilities Other current tax liabilities, net Other current financial liabilities Other of current financial liabilities Other form malpamation Others Others Other form operating activities (A) Interest of current financial liabilities Other of the financial liabilities Other form of sevent and sevent form of sevent fo		571.137		-593.37	
Adjustments for increase / (decrease) in operating liabilities: Trade payables Borrowings Other current financial liabilities Other current liabilities 9,713 3,94 Other current liabilities 1-1,014 25,86 Current tax liabilities, net 1-4,531 38,00 Deferred tax on amalgamation Cash generated from operations Net income tax paid let cash flow from operating activities (A) 105,986 106,000 107,986 107,000 107,000 108,000		-1.000		-	
Trade payables Borrowings Other current financial liabilities Other current tax liabilities Other current tax liabilities, of 5.5.85 Other current tax liabilities of 5.5.85 Other current tax liabilities, of 5.5.86 Other current tax liabilities of 5.5.86 Other cu	Other Current financial Assets	9.350		-3.96	
Trade payables Borrowings -159.859 -203.36 Borrowings 9.713 3.94 Other current financial liabilities 9.713 3.94 Other current financial liabilities -1.014 -25.86 Current tax liabilities, net -14.531 -32.36 Frovisions 6.500 38.00 Deferred tax on amalgamation 216.223 Deferred tax paid -20.237 Deferred tax p					
Borrowings Other current financial liabilities Other current financial liabilities Current tax liabilities, net Provisions Current tax liabilities, net Provisions Effect day on amalgamation Cash generated from operations Net income tax paid ete cash flow from operating activities (A) 195.986 CASH FLOW FROM INVESTING ACTIVITIES Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below) Proceeds from maturiy of fixed deposits Investment - Subsidiaries - Others - Others - Others - Others - Others dividend from mutual funds let cash (used in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES - CASH FLOW FROM FINANCING ACTIVITIES - Others - Others dividend from mutual funds let cash (used in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES - Finance costs - 158.982 - 155.54 - 67.74 - 77.4 - 78.99.035 - 67.74 - 78.99.035 - 67.74 - 78.99.035 - 67.74 - 78.99.035 - 67.74 - 78.99.035 - 67.74 - 78.99.035 - 67.74 - 78.99.035 - 67.74 - 78.99.035 - 67.74 - 78.99.035 - 67.74 - 78.99.035 - 67.74 - 78.99.035 - 67.75 - 78.99.035 - 67.75 - 78.99.035 - 67.76 - 79.035 - 67.77 - 79.036 - 79.035 - 79.					
Other current financial liabilities 9.713 3.94 Other current liabilities -1.014 -25.86 Current tax liabilities, net -1.014 -25.86 Provisions 6.500 38.00 Deferred tax on amalgamation Cash generated from operations Net income tax paid -20.237 Net income operating activities (A) -101.79 Net income of fixed deposits -20.000 -25.000 Net income maturity of fixed deposits -20.000 -20.000 Net income received receive		-159.859		-203.36	
Other current liabilities -1.014 -25.86 Current tax liabilities, net -14.531 -32.36 Provisions -38.00 Deferred tax on amalgamation Cash generated from operations Net income tax paid let cash flow from operating activities (A) CASH FLOW FROM INVESTING ACTIVITIES Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below) Proceeds from maturity of fixed deposits Investment - Subsidiaries -20.000 -141.50 - Others - Others - dividend from mutual funds let cash (used in) / flow from investing activities (B) -CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs -158.982 -155.54 Repayment of Borrowings -99.035 -167.74 Repayment of Short term Borrowings 19.658 -16.70 Govt Grants Other equity Adjustment et cash flow (used in) financing activities (C) et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash					
Current tax liabilities, net 1-14.531 -32.36 Provisions 6.500 38.00 Deferred tax on amalgamation Cash generated from operations Net income tax paid -20.237 let cash flow from operating activities (A) LCASH FLOW FROM INVESTING ACTIVITIES Capital expenditure on fixed assets, including capital advances (Refer Note (ii) below) Proceeds from maturiy of fixed deposits Investment - Subsidiaries - 20.000 - 141.50 O.60 COMPRISE -		9.713		3.94	
Provisions Deferred tax on amalgamation Cash generated from operations Net income tax paid Let cash flow from operating activities (A) LCASH FLOW FROM INVESTING ACTIVITIES Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below) Proceeds from maturiy of fixed deposits Investment - Subsidiaries - Others - Others - Others - Others - Others - dividend from mutual funds let cash (used in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs Repayment of Borrowings - 158.982 Repayment of Short term Borrowings - 19.058 Repayment of Short term Borrowings - 19.058 Repayment of Short term Borrowings - 19.058 - 16.70 Govt Grants - 100.968 - 68.938 et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents sha and cash equivalents at the end of the year (Refer Note (i) below) Comprises: lances with Banks - 20.237 - 195.986 - 20.237 - 20.237 - 20.237 - 20.203 - 20.237 - 20.203 - 2		-1.014		-25.86	
Deferred tax on amalgamation Cash generated from operations Net income tax paid let cash flow from operating activities (A) CASH FLOW FROM INVESTING ACTIVITIES Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below) Proceeds from maturity of fixed deposits Investment - Subsidiaries - Others Dividend income received - Subsidiary - Others - dividend from mutual funds let cash (used in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs Repayment of Borrowings Repayment of Borrowings Repayment of short term Borrowings Other equity Adjustment et cash flow (used in) financing activities (C) - CASH Flow Flow and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents Comprises: alances with Banks 0.00 - Others - 135.982 - 155.54 - 68.938 - 70.00		-14.531		-32.36	
Cash generated from operations Net income tax paid Net income tax paid Net cash flow from operating activities (A) CASH FLOW FROM INVESTING ACTIVITIES Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below) Proceeds from maturity of fixed deposits Investment - Subsidiaries - Others O.929 Dividend income received - Subsidiary - Others - dividend from mutual funds let cash (used in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs Repayment of Borrowings Repayment of short term Borrowings Oovt Grants Other equity Adjustment et cash flow (used in) financing activities (C) et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents alances with Banks O.000		6.500		38.00	
Net income tax paid let cash flow from operating activities (A) 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.986 101.79 -85.66 (Refer Note (iii) below) Proceeds from maturiy of fixed deposits Investment - Subsidiaries - 20.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 0.000 - 141.50 - 1.000 - 1.0					
Act cash flow from operating activities (A) 195.986 195.686 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.986 195.999 195.986 195.986 195.986 195.986 195.986 188.67 188.67 195.54 195.554 196.78 196.78 196.78 196.78 196.78 196.88			216.223		259.25
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below) Proceeds from maturiy of fixed deposits Investment - Subsidiaries - Others Dividend income received - Subsidiary - Others - dividend from mutual funds let cash (used in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs - 158.982 - 155.54 Repayment of Borrowings - 99.035 Govt Grants Other equity Adjustment Let cash flow (used in) financing activities (C) et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks Oddoc Chebers -20.000 -141.50 -0.929 -0.60 -141.50 -0.929 -0.60 -141.50 -0.929 -0.929 -0.60 -141.50 -0.929 -0.60 -141.50 -0.929 -0.60 -141.50 -0.929 -0.60 -141.50 -0.929 -0.60 -141.50 -0.929 -0.60 -141.50 -0.929 -0.60 -141.50 -0.929 -0.60 -141.50 -0.929 -0.60 -141.50 -141.50 -1.929 -1.929 -1.928 -1.928 -1.928 -1.928 -1.928 -1.928 -1.928 -1.928 -1.928 -1.928 -1.928 -1.928 -1.928 -1.			-20.237		-34.77
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below) Proceeds from maturiy of fixed deposits Investment - Subsidiaries - Others - Others - Others - Others - Subsidiary - Others - dividend income received - Subsidiary - Others - dividend from mutual funds let cash (used in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs - 158.982 - 155.54 Repayment of Borrowings - 99.035 - 67.74 Repayment of short term Borrowings - 19.658 - 16.70 Govt Grants Other equity Adjustment et cash flow (used in) financing activities (C) - 68.938 et (decrease) in Cash and cash equivalents (A+B+C) - Sash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 -	Net cash flow from operating activities (A)		195.986		224.48
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below) Proceeds from maturiy of fixed deposits Investment - Subsidiaries - Others - Others - Others - Others - Subsidiary - Others - dividend income received - Subsidiary - Others - dividend from mutual funds let cash (used in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs - 158.982 - 155.54 Repayment of Borrowings - 99.035 - 67.74 Repayment of short term Borrowings - 19.658 - 16.70 Govt Grants Other equity Adjustment et cash flow (used in) financing activities (C) - 68.938 et (decrease) in Cash and cash equivalents (A+B+C) - Sash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 - 141.50 - 20.000 -	CACUE				
(Refer Note (iii) below) Proceeds from maturiy of fixed deposits Investment - Subsidiaries - Others - Others - Others - Others - Others - dividend income received - Subsidiary - Others - dividend from mutual funds let cash (used in) / flow from investing activities (B) - 120.864 - CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares - 158.982 - 155.54 Repayment of Borrowings - 99.035 - 67.74 Repayment of short term Borrowings - 19.658 - 16.70 Govt Grants - Other equity Adjustment - Let cash flow (used in) financing activities (C) - 68.938 - 61.85					
Proceeds from maturity of fixed deposits Investment - Subsidiaries - Others - Others - Others - Subsidiary - Others - dividend from mutual funds let cash (used in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs - 158.982 - 155.54 Repayment of Borrowings - 99.035 Repayment of short term Borrowings - 19.658 Govt Grants - 10.968 et cash flow (used in) financing activities (C) - 68.938 et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks 0.00		-101.79		-85.66	
Investment - Subsidiaries - Others Others Others Others Others Others Others Others - Subsidiary Others - dividend from mutual funds Interest (ash (used in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs Finance cost					
- Subsidiaries - 20.000 0 0.929 0 0.60 0.929 0 0.60 0.929 0 0.60 0.929 0 0.60 0.929 0 0.60 0.929 0 0.60 0.929 0 0.60 0.929 0 0.60 0.929 0 0.60 0.929 0 0.60 0.929 0 0.60 0.929 0 0.60 0.929 0 0.60 0 0.929 0 0.60 0 0.929 0 0.60 0 0.929 0 0.60 0 0.929 0 0.60 0 0.929 0 0.60 0 0.929 0 0.60 0 0.929 0 0.60 0 0.929 0 0.60 0 0.929 0 0.60 0 0.60 0 0.929 0 0.60 0 0.60 0 0.929 0 0.60 0 0.60 0 0.929 0 0.60 0 0.60 0 0.929 0 0.60 0 0.60 0 0.929 0 0.60 0 0.60 0 0.929 0 0.60 0 0.929 0 0.60 0 0.60 0 0.929 0 0.60 0 0.60 0 0.929 0 0.60 0				-	
Others Others Others Others Others Others Others - Others - dividend income received - Subsidiary - Others - dividend from mutual funds et cash (used in) / flow from investing activities (B) -120.864 -120					
Dividend income received - Subsidiary - Others - dividend from mutual funds let cash (used in) / flow from investing activities (B) -120.864 -CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares finance costs -158.982 -155.54 Repayment of Borrowings -99.035 -67.74 Repayment of short term Borrowings 19.658 -16.70 Govt Grants -0ther equity Adjustment et cash flow (used in) financing activities (C) et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks -120.864 -120.864 -120.864 -120.864 -180.67 -158.982 -155.54 -67.74 -67				-141.50	
- Subsidiary - Others - dividend from mutual funds let cash (used in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs Floating costs Repayment of Borrowings Formula for term		0.929		0.60	
- Others - dividend from mutual funds let cash (used in) / flow from investing activities (B) - CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs Repayment of Borrowings Repayment of short term Borrowings Govt Grants Other equity Adjustment et cash flow (used in) financing activities (C) et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks 0.00					
Let cash (used in) / flow from investing activities (B) -120.864					
CASH FLOW FROM FINANCING ACTIVITIES Proceeds from issue of equity shares Finance costs Repayment of Borrowings Repayment of short term Borrowings Govt Grants Other equity Adjustment et cash flow (used in) financing activities (C) et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks O.00					
Proceeds from issue of equity shares Finance costs Repayment of Borrowings Repayment of short term Borrowings Govt Grants Other equity Adjustment et cash flow (used in) financing activities (C) ash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks 0.00	et cash (used in) / flow from investing activities (B)		-120.864		-226.56
Proceeds from issue of equity shares Finance costs Repayment of Borrowings Repayment of short term Borrowings Govt Grants Other equity Adjustment et cash flow (used in) financing activities (C) ash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks 0.00	CASH FLOW FROM FINANCING A CTURE				
Finance costs Repayment of Borrowings Repayment of short term Borrowings Govt Grants Other equity Adjustment et cash flow (used in) financing activities (C) et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks O.00					
Repayment of Borrowings -135.54 -67.74 Repayment of short term Borrowings 19.658 -67.74 Repayment of short term Borrowings 19.658 -16.70 Govt Grants 100.968 56.48 et cash flow (used in) financing activities (C) 6.185 ash and cash equivalents at the beginning of the year 7.525 Effect of exchange differences on translation of foreign currency Cash and cash equivalents at the end of the year (Refer Note (i) below) 13.71 Comprises: alances with Banks 0.00				188,67	
Repayment of short term Borrowings Govt Grants Other equity Adjustment et cash flow (used in) financing activities (C) et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks 0.00				-155.54	
Govt Grants Other equity Adjustment et cash flow (used in) financing activities (C) et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents ash and cash equivalents ash and cash equivalents ash and sequivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks 0.00			1	-67.74	
Other equity Adjustment et cash flow (used in) financing activities (C) et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks 0.00		19.658		-16.70	
et cash flow (used in) financing activities (C) et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks 0.00		-		-	
et (decrease) in Cash and cash equivalents (A+B+C) ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks 0.00		100.968		56.48	
ash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks 0.00	et cash flow (used in) financing activities (C)		-68.938		5.16
ash and cash equivalents at the beginning of the year Feffect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: Idances with Banks 0.00	et (decrease) in Cash and each and later				
Effect of exchange differences on translation of foreign currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks 0.00					3.08
currency Cash and cash equivalents ash and cash equivalents at the end of the year (Refer Note (i) below) 13.71 Comprises: alances with Banks 0.00			7.525		4.44
ash and cash equivalents at the end of the year (Refer Note (i) below) Comprises: alances with Banks 0.00					
Comprises: alances with Banks 0.00					
alances with Banks 0.00	Comprises:		13.71		7.52
Others					
13.71					0.00
	Duleis				7.52
13.71					7.52
By Order of the Board For Concord Drugs Limited					

Place: Hyderabad Date: 30.05.2024